CN113646330A - 工程化cd25多肽及其用途 - Google Patents

工程化cd25多肽及其用途 Download PDF

Info

Publication number
CN113646330A
CN113646330A CN201980088633.3A CN201980088633A CN113646330A CN 113646330 A CN113646330 A CN 113646330A CN 201980088633 A CN201980088633 A CN 201980088633A CN 113646330 A CN113646330 A CN 113646330A
Authority
CN
China
Prior art keywords
antibody
cdr
engineered
binding
engineered polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088633.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·格雷文
P·T·吉普
M·斯里尼瓦桑
A·莫里
K·E·豪瑟
J·R·威利斯
C·A·摩尔
C·巴雷特
A·T·田口
A·埃斯特莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yibio Co
Original Assignee
Rubik Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubik Therapy Co ltd filed Critical Rubik Therapy Co ltd
Publication of CN113646330A publication Critical patent/CN113646330A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980088633.3A 2018-11-14 2019-11-14 工程化cd25多肽及其用途 Pending CN113646330A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767431P 2018-11-14 2018-11-14
US62/767,431 2018-11-14
US201962902334P 2019-09-18 2019-09-18
US62/902,334 2019-09-18
PCT/US2019/061567 WO2020102603A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN113646330A true CN113646330A (zh) 2021-11-12

Family

ID=70731914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088633.3A Pending CN113646330A (zh) 2018-11-14 2019-11-14 工程化cd25多肽及其用途

Country Status (6)

Country Link
US (1) US12441803B2 (https=)
EP (1) EP3880698A4 (https=)
JP (3) JP7695881B2 (https=)
CN (1) CN113646330A (https=)
CA (1) CA3120102A1 (https=)
WO (1) WO2020102603A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585918A (zh) * 2019-05-31 2022-06-03 鲁比克治疗股份有限公司 中尺度工程化肽和选择方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
WO2021119261A1 (en) * 2019-12-10 2021-06-17 Homodeus, Inc. Generative machine learning models for predicting functional protein sequences
MX2023005032A (es) * 2020-11-10 2023-05-16 Scripps Research Inst Anticuerpos para tratamientos con opioides.
WO2022119863A1 (en) * 2020-12-01 2022-06-09 Rubryc Therapeutics, Inc. Generalized scaffolds for polypeptide display and uses thereof
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN114384245B (zh) * 2022-03-24 2022-06-24 江苏美克医学技术有限公司 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US20120276125A1 (en) * 2011-04-29 2012-11-01 Oliver Ast Novel immunoconjugates
WO2018167104A1 (en) * 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US8586709B2 (en) 2007-09-25 2013-11-19 Pastoral Greenhouse Research Limited Cell-permeabilising peptides and polypeptides for microbial cells
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3191121B1 (en) * 2014-09-10 2020-05-27 The University of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US10377815B2 (en) 2015-05-05 2019-08-13 Albert Einstein College Of Medicine Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
EP3612565A4 (en) * 2017-04-18 2021-06-16 R-Pharm Overseas, Inc. ANTI-PD-L1 ANTIBODIES AND USES THEREOF
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
JP7579812B2 (ja) 2019-05-31 2024-11-08 アイバイオ， インク． メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US20120276125A1 (en) * 2011-04-29 2012-11-01 Oliver Ast Novel immunoconjugates
WO2018167104A1 (en) * 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NH TRIER ET AL: "Production and characterization of peptide antibodies", METHODS, vol. 56, no. 2, pages 136 - 144, XP055294033, DOI: 10.1016/j.ymeth.2011.12.001 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585918A (zh) * 2019-05-31 2022-06-03 鲁比克治疗股份有限公司 中尺度工程化肽和选择方法

Also Published As

Publication number Publication date
JP7695881B2 (ja) 2025-06-19
JP2026065087A (ja) 2026-04-14
CA3120102A1 (en) 2020-05-22
JP2025026923A (ja) 2025-02-26
JP2022513043A (ja) 2022-02-07
EP3880698A4 (en) 2022-11-30
US20230016112A1 (en) 2023-01-19
WO2020102603A1 (en) 2020-05-22
EP3880698A1 (en) 2021-09-22
US12441803B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
US20220081472A1 (en) Meso-scale engineered peptides and methods of selecting
US20040110226A1 (en) Antibody optimization
JP6391574B2 (ja) 種間標的内交差反応性を有する抗体分子を産生する方法
CN114746440A (zh) 新型多肽复合物
RU2639505C2 (ru) Библиотека fv на основе комбинаций белков и способ ее получения
JP7217772B2 (ja) 三次元構造に基づくヒト化方法
CA2915956A1 (en) Rational method for solubilising proteins
CN118702814A (zh) 一种抗ngf单克隆抗体及其应用
Luthra et al. Human antibody bispecifics through phage display selection
JP7691234B2 (ja) 抗体の抗原に対する親和性を向上させる方法及びその利用
HK40063514A (en) Engineered cd25 polypeptides and uses thereof
CN113677691A (zh) 选择功能界面模拟物的方法及其组合物
Team et al. Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2
JP2024523921A (ja) 特異的バインダーの選択手段及び方法
CN101426526B (zh) 使用工程诱杀蛋白的液相生物淘选方法
Chen et al. Improved isolation of anti-rhTNF-α scFvs from phage display library by bioinformatics
Rodríguez Gómez et al. Generation and NGS profiling of naïve rabbit antibody libraries for efficient monoclonal antibody selection
Pszolla Computational design of novel interactions in conventional and heavy chain antibodies
HK40098558A (zh) 基於三维结构的人源化方法
CN117836308A (zh) 用于选择特异性结合剂的手段和方法
HK40076302B (zh) 新型多肽复合物
HK40023878B (zh) 基於三维结构的人源化方法
HK1132177B (en) Solution phase biopanning method using engineered decoy proteins
HK1215722B (zh) 基於蛋白结合的fv文库及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063514

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230216

Address after: Texas, USA

Applicant after: Yibio Co.

Address before: California, USA

Applicant before: Rubik therapy Co.,Ltd.